Journal Article (Review Article) DZNE-2025-00941

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
SynNeurGe: The road ahead for a biological definition of Parkinson's disease.

 ;

2025
IOS Press Amsterdam

Journal of Parkinson's Disease 15(5), 931 - 938 () [10.1177/1877718X241298194]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: While significant progress has been made in treating Parkinson's disease (PD) symptoms, disease-modifying therapies (DMTs) have consistently failed. To address the underlying molecular mechanisms of PD, two biology-based criteria have been proposed: the 'Synucleinopathy-Neurodegeneration-Genetics' (SynNeurGe) and 'neuronal α-synuclein disease' (NSD) frameworks. Both frameworks emphasize the importance of biological markers over clinical symptoms. They recognize α-synuclein aggregation and genetic mutations (such as SNCA) as key diagnostic elements, with α-synuclein seed amplification assays (SAA) in cerebrospinal fluid (CSF) used to detect early disease stages. Dopaminergic neurodegeneration, measured by DAT imaging, is also central to both frameworks. These shared features aim to improve early diagnosis and precision medicine for PD. However, SynNeurGe provides a broader, more flexible framework that integrates α-synuclein pathology (S), neurodegeneration (N), and genetics (G), linked to clinical features (C). It aims to accommodate the complexity of PD and related Lewy body diseases, facilitating research on targeted DMTs. In contrast, NSD focuses specifically on PD and Lewy body dementia, introducing a staging system (NSD-ISS) based on biological markers and clinical impairment, helping track disease progression from preclinical to symptomatic stages. Despite their differences, both approaches highlight the need for more specific biomarkers and prospective studies to improve early intervention and personalized treatment. Harmonizing SynNeurGe and NSD concepts will be key in creating a universally accepted framework for precise PD diagnosis and therapy development.

Keyword(s): Humans (MeSH) ; Parkinson Disease: diagnosis (MeSH) ; Parkinson Disease: genetics (MeSH) ; Parkinson Disease: metabolism (MeSH) ; Parkinson Disease: pathology (MeSH) ; alpha-Synuclein: metabolism (MeSH) ; alpha-Synuclein: genetics (MeSH) ; Biomarkers: cerebrospinal fluid (MeSH) ; Synucleinopathies: diagnosis (MeSH) ; Synucleinopathies: genetics (MeSH) ; biological definition ; genetics ; neurodegeneration ; parkinson's disease ; synuclein ; alpha-Synuclein ; Biomarkers

Classification:

Contributing Institute(s):
  1. Clinical Research (Munich) (Clinical Research (Munich))
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025
Database coverage:
Medline ; Creative Commons Attribution-NonCommercial CC BY-NC 4.0 ; DOAJ ; OpenAccess ; Article Processing Charges ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Institute Collections > M DZNE > M DZNE-Clinical Research (Munich)
Document types > Articles > Journal Article
Full Text Collection
Public records
Publications Database

 Record created 2025-08-11, last modified 2025-08-31


OpenAccess:
Download fulltext PDF Download fulltext PDF (PDFA)
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)